Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study, published in the International Journal of Molecular Science ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain ...
Modelling indicates that over a 20-year period, a national screening programme could detect around 9,000 lung cancers and potentially save more than 6,000 lives – an estimated 300 lives each year.
February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...
Australia screens for lung cancer. England screens for lung cancer. New Zealand does not, yet it is the country’s deadliest cancer. Lung cancer kills more Kiwis than any other cancer and is the fourth ...
As a nonsmoker lung cancer hasn't been a concern of mine, but I recently heard it can affect people who have never smoked. If ...
The trust that runs the major hospitals in Shropshire is taking part in a new lung cancer study to find alternative ...
The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.
The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December ...
The approval expands Boehringer's ⁠presence in the market for targeted lung cancer ​therapies, where it will compete ​with other treatments, including Bayer's Hyrnuo.